Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line

Inge Van Outersterp; Femke M Hormann; Alex Q Hoogkamer; Aurélie Boeree; Stijn A Van den Broek; Monique L Den Boer; Judith M Boer

doi:10.3324/haematol.2022.281712

Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line

Haematologica. 2023 Oct 1;108(10):2859-2864. doi: 10.3324/haematol.2022.281712.

Authors

Inge Van Outersterp¹, Femke M Hormann², Alex Q Hoogkamer¹, Aurélie Boeree¹, Stijn A Van den Broek¹, Monique L Den Boer², Judith M Boer³

Affiliations

¹ Princess Máxima Center for pediatric oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands.
² Princess Máxima Center for pediatric oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands; Erasmus MC - Sophia Children's Hospital, Department of Pediatric Oncology and Hematology, Rotterdam, Netherlands.
³ Princess Máxima Center for pediatric oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands. j.m.boer-20@prinsesmaximacentrum.nl.

No abstract available

Publication types

Letter

MeSH terms

Cell Line
Humans
MEF2 Transcription Factors / genetics
MEF2 Transcription Factors / metabolism
Oncogene Proteins, Fusion / genetics
Oncogene Proteins, Fusion / metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics
Transcription Factors

Substances

Transcription Factors
Oncogene Proteins, Fusion
BCL9 protein, human
MEF2D protein, human
MEF2 Transcription Factors

Grants and funding

Funding: The authors would like to thank Foundation Pediatric Oncology Center Rotterdam (SKOCR), the Dutch Cancer Society grant KWF-10482, and the KiKa Foundation Kika-264 grant for their support.